TL;DR
Researchers have developed novel "molecular bowls" that can effectively bind to the toxic anticancer drug methotrexate (MTX). These bowls show promise as a new therapeutic strategy to remove excess MTX from patients, potentially mitigating severe side effects like kidney and liver damage.
What Problem Does This Paper Address?
Methotrexate (MTX) is a vital drug used to treat various cancers and autoimmune diseases. However, a significant percentage of patients undergoing high-dose MTX treatment experience severe side effects, including acute kidney injury, myelosuppression, and hepatotoxicity, which can even lead to multiorgan failure. While current countermeasures like leucovorin and urine alkalinization exist, they are not always sufficient, especially in severe cases. A more advanced solution, glucarpidase, is expensive and has limitations in its distribution and efficacy. This paper addresses the critical need for an alternative, cost-effective, and efficient method to sequester and remove excess MTX from the body, thereby preventing or treating its toxic effects.
Methods
The researchers synthesized two novel molecular bowls, designated 1<sup>6+</sup> and 2<sup>6+</sup>, based on a tribenzotriquinacene (TBTQ) core functionalized with pyridinium units. The synthesis involved a two-step process starting from hexabromo-tribenzotriquinacene.
Key techniques employed include:
- Nuclear Magnetic Resonance (NMR) Spectroscopy: Used extensively for structural characterization, conformational analysis (including variable-temperature NMR), and studying self-association of the bowls. ¹H NMR, ¹H-¹H NOESY, ¹³C-¹H HMBC, and ¹³C-¹H HSQC were utilized.
- Mass Spectrometry (ESI-MS): Employed to confirm molecular weights and identify complex formation.
- Computational Studies:
- Density Functional Theory (DFT): Used for energy minimization of conformers and to understand electronic properties.
- Molecular Dynamics (MD) Simulations: Investigated the conformational dynamics and flexibility of the molecular bowls.
- Monte Carlo (MC) Simulations: Used in conjunction with computational protocols to predict the binding pose of MTX within the bowls.
- X-ray Diffraction: Provided detailed structural information of one of the synthesized bowls (1<sup>6+</sup>) in the solid state, confirming its conformation and packing.
- MTS Assay: A standard colorimetric assay used to evaluate the in vitro biocompatibility and cytotoxicity of the molecular bowls on human kidney (HEK293) and liver cancer (HepG2) cell lines.
A novel computational protocol was also developed to predict the binding pose of MTX within the bowls using NMR shielding data and root-mean-squared error (RMSE) analysis.
Datasets
Not explicitly discussed as "datasets" in the traditional machine learning sense. The study relies on:
- Synthesized molecular bowls (1<sup>6+</sup> and 2<sup>6+</sup>): These are the primary "materials" studied.
- Methotrexate (MTX): The guest molecule used for complexation studies.
- Standard cell lines (HEK293 and HepG2): Used for biocompatibility testing.
- Existing literature data: Used for comparison and context (e.g., MTX folding, known MTX binders).
Key Insights and Ideas
- Molecular Bowls as MTX Binders: The designed molecular bowls, with their curved, nonpolar TBTQ core and positively charged pyridinium rim, are well-suited to encapsulate the folded structure of MTX.
- Dual Binding Mechanism: The bowls appear to bind MTX through a combination of π-π stacking and C-H-π interactions between the drug's aromatic rings and the bowl's cavity, along with ion-pairing between MTX's glutamate moiety and the pyridinium units.
- Conformational Flexibility and Rigidity: While the TBTQ core of the bowls is rigid, the pyridinium rim exhibits conformational flexibility, allowing for adaptation to the guest molecule.
- Self-Association in Water: The amphiphilic nature of the bowls leads to self-association in aqueous media, which was characterized and found to occur in a nucleation-followed-by-oligomerization pathway. This self-association was considered and accounted for in the MTX binding studies.
- Computational Protocol for Binding Pose Prediction: The development of a computational method combining NICS calculations, Monte Carlo simulations, and NMR data analysis provides a powerful tool for predicting host-guest binding poses, applicable beyond this specific system.
- Bowl 2<sup>6+</sup> as a Superior Binder: Bowl 2<sup>6+</sup> demonstrated a significantly higher binding affinity for MTX compared to bowl 1<sup>6+</sup>, reaching micromolar stability, which is crucial for therapeutic applications.
- Biocompatibility: Both molecular bowls exhibited minimal toxicity to kidney and liver cells at relevant concentrations, suggesting they are safe candidates for further development.
Key Results
- Synthesis: Molecular bowls 1<sup>6+</sup> and 2<sup>6+</sup> were synthesized in good yields (25% overall for a two-step process).
- Binding Affinity:
- Binary complex [MTX⊂1<sup>6+</sup>]<sup>4+</sup>: K<sub>1</sub> = 4.4 ± 3.1 × 10<sup>4</sup> M<sup>-1</sup>
- Ternary complex [MTX<sub>2</sub>⊂1<sup>6+</sup>]<sup>4+</sup>: K<sub>2</sub> = 1.9 ± 0.3 × 10<sup>3</sup> M<sup>-1</sup>
- Binary complex [MTX⊂2<sup>6+</sup>]<sup>4+</sup>: K<sub>1</sub> = 2.17 ± 0.11 × 10<sup>5</sup> M<sup>-1</sup> (approximately 4.6 µM)
- Ternary complex [MTX<sub>2</sub>⊂2<sup>6+</sup>]<sup>4+</sup>: K<sub>2</sub> = 1.88 ± 0.01 × 10<sup>3</sup> M<sup>-1</sup>
- Computational Binding Pose: The computational protocol identified folded MTX within the bowls, with the pteridine moiety interacting with the bowl's interior and the p-aminobenzoic group facing outward. Bowl 2<sup>6+</sup> was found to have smaller gaps, leading to more effective encapsulation and higher stability.
- Biocompatibility: MTS assays showed that bowls 1<sup>6+</sup> and 2<sup>6+</sup> had minimal adverse effects on HEK293 and HepG2 cell viability at concentrations up to 100 µM, with IC<sub>50</sub> values greater than 100 µM.
Limitations and Future Work
- Self-Association: While the study accounted for self-association, minimizing it in future bowl designs could further enhance their efficiency as sequestering agents.
- Specificity: Future work will focus on tuning the bowl structure to achieve selective recognition of MTX in the presence of similar molecules like leucovorin and folic acid.
- In Vivo Studies: The current study is in vitro. The next logical step is to evaluate the efficacy and safety of these molecular bowls in vivo for MTX overdose treatment.
- Further Structural Optimization: Exploring variations in the bowl's macrocyclic rim and TBTQ core could lead to even more potent and selective MTX binders.
- Application to Other Drugs: The developed computational protocol and the general concept of molecular bowls could be extended to sequester other toxic drugs.
Summary updated